JP2011502169A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502169A5
JP2011502169A5 JP2010532276A JP2010532276A JP2011502169A5 JP 2011502169 A5 JP2011502169 A5 JP 2011502169A5 JP 2010532276 A JP2010532276 A JP 2010532276A JP 2010532276 A JP2010532276 A JP 2010532276A JP 2011502169 A5 JP2011502169 A5 JP 2011502169A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
pharmaceutically acceptable
meclizine
chemically modified
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010532276A
Other languages
English (en)
Japanese (ja)
Other versions
JP5462797B2 (ja
JP2011502169A (ja
Filing date
Publication date
Priority claimed from US11/980,845 external-priority patent/US8138192B2/en
Application filed filed Critical
Publication of JP2011502169A publication Critical patent/JP2011502169A/ja
Publication of JP2011502169A5 publication Critical patent/JP2011502169A5/ja
Application granted granted Critical
Publication of JP5462797B2 publication Critical patent/JP5462797B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010532276A 2007-10-31 2008-10-31 注射可能なメクリジン製剤および方法 Expired - Fee Related JP5462797B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/980,845 US8138192B2 (en) 2007-10-31 2007-10-31 Injectable meclizine formulations and methods
US11/980,845 2007-10-31
PCT/US2008/081973 WO2009059120A2 (en) 2007-10-31 2008-10-31 Injectable meclizine formulations and methods

Publications (3)

Publication Number Publication Date
JP2011502169A JP2011502169A (ja) 2011-01-20
JP2011502169A5 true JP2011502169A5 (enExample) 2012-02-02
JP5462797B2 JP5462797B2 (ja) 2014-04-02

Family

ID=40583655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532276A Expired - Fee Related JP5462797B2 (ja) 2007-10-31 2008-10-31 注射可能なメクリジン製剤および方法

Country Status (10)

Country Link
US (2) US8138192B2 (enExample)
EP (1) EP2219606B1 (enExample)
JP (1) JP5462797B2 (enExample)
AU (1) AU2008318536B2 (enExample)
CA (1) CA2704430C (enExample)
ES (1) ES2657937T3 (enExample)
NZ (1) NZ584942A (enExample)
PT (1) PT2219606T (enExample)
WO (1) WO2009059120A2 (enExample)
ZA (1) ZA201003524B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1161509A2 (en) * 2010-06-04 2012-07-27 全球药物科技有限公司 Oral meclizine aqueous formulations with taste flavoring agent
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2019178536A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Mtor inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60204712A (ja) 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6699505B2 (en) 2000-10-17 2004-03-02 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by compexing with cyclodextrins
US20060120967A1 (en) 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils

Similar Documents

Publication Publication Date Title
JP2019131596A5 (enExample)
JP2010525059A5 (enExample)
HUP0105160A2 (hu) Ras-farnezil transzferáz inhibitor és béta-ciklodextrin-7-szulfobutil-éter vagy 2-(hidroxi-propil)-béta-ciklodextrin komplexe és eljárás előállítására és ezeket tartalmazó gyógyszerkészítmények
EA201370175A1 (ru) Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2002102383A1 (fr) Preparation de cilostazol aqueuse pour injections
JP5781152B2 (ja) アセトアミノフェン組成物
JP2011502169A5 (enExample)
CA2494157A1 (en) Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof
KR101829685B1 (ko) 안정성 및 용해도가 개선된 주사용 조성물
US11141417B2 (en) Voriconazole inclusion complexes
UY38431A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
JP2006516642A (ja) 薬物製剤およびメチル化シクロデキストリン結晶を用いた送達
CN100508969C (zh) 紫杉烷环糊精包合物纳米粒及其制备方法
CN104027310A (zh) 一种法罗培南钠颗粒剂及其制备方法
CN102274171A (zh) 一种奥沙利铂注射剂
JP6084371B2 (ja) 薬剤安定化医薬組成物
US11986486B2 (en) Aqueous compositions of bortezomib
AU2008340179B2 (en) Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
Doijad et al. Effect of processing variables on dissolution and solubility of piroxicam: Hydroxypropyl-β-cyclodextrin inclusion complexes.
Onyeji Cyclodextrin complexes: utility in improving drug bioavailability and other applications
WO2021144936A1 (ja) 有機化合物包接フラーレンを含む組成物並びにそれを含む化粧品及び外用組成物
EP2968595A2 (en) Voriconazole formulations
WO2024102547A1 (en) Anhydrous compositions of polysorbates and cyclodextrins for shelf stable drug combinations with macrocyclic lactone complexes
CA2514878C (en) Drug formulation and delivery using crystalline methylated cyclodextrins
KR20220137028A (ko) 아스파시타라빈 약제학적 조성물 및 이의 용도